© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection
Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, Australia-
Western Australian Institute for Medical Research, Australia
* Cell Signalling Laboratory, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. Tel: +61-8-6488-1348; fax: +61-8-6488-1148. Email address: marieb{at}cyllene.uwa.edu.au
Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells. As recently reviewed by Smith et al. [Cardiovasc. Res. 59 (2003) 538–548], Epo can also act within the cardiovascular system with effects in thrombosis and hypertension as well as actions on platelets, vascular endothelium and smooth muscle, and myocytes of the heart. Here, the actions of Epo to protect neuronal cells of the brain are first evaluated and parallel actions of Epo in cardioprotection are then drawn. Thus, with recent reports of Epo receptor (EpoR) expression by cardiac myocytes, it could be predicted that Epo initiates direct protective signalling events. This is supported by five independent studies published in 2003 showing Epo protects cardiac myocytes following ischemia/reperfusion. Importantly, these protective actions have been observed in vitro and in vivo. The former suggests the direct actions of Epo to prevent myocyte death independently of its effects on red blood cell number or cells other than cardiac myocytes. The latter demonstrates the potential for Epo in the treatment of the heart post-infarction, decreasing the numbers of apoptotic myocytes, limiting infarct expansion and attenuating the post-infarct deterioration in haemodynamic function. These beneficial effects of Epo should stimulate further research into the actions of Epo.
KEYWORDS Apoptosis; Phosphatidyl inositol 3' kinase; In vitro cardioprotection; In vivo cardioprotection; Ischemia/reperfusion damage
Time for primary review 29 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Mihov, J. Vogel, M. Gassmann, and A. Bogdanova Erythropoietin activates nitric oxide synthase in murine erythrocytes Am J Physiol Cell Physiol, August 1, 2009; 297(2): C378 - C388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al. Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hirschler-Laszkiewicz, Q. Tong, K. Conrad, W. Zhang, W. W. Flint, A. J. Barber, D. L. Barber, J. Y. Cheung, and B. A. Miller TRPC3 Activation by Erythropoietin Is Modulated by TRPC6 J. Biol. Chem., February 13, 2009; 284(7): 4567 - 4581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rabie and H. H. Marti Brain Protection by Erythropoietin: A Manifold Task Physiology, October 1, 2008; 23(5): 263 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Mehta Erythropoietin in cardioprotection: does it have a future or is it all in the past? Cardiovasc Res, September 1, 2008; 79(4): 549 - 550. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Elfar, J. A. Jacobson, J. E. Puzas, R. N. Rosier, and M. J. Zuscik Erythropoietin Accelerates Functional Recovery After Peripheral Nerve Injury J. Bone Joint Surg. Am., August 1, 2008; 90(8): 1644 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yokomaku, T. Sugimoto, S. Kume, S.-i. Araki, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Nitta, M. Haneda, D. Koya, et al. Asialoerythropoietin Prevents Contrast-Induced Nephropathy J. Am. Soc. Nephrol., February 1, 2008; 19(2): 321 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ramond, E. Sartorius, M. Mousseau, C. Ribuot, and M. Joyeux-Faure Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts Experimental Biology and Medicine, January 1, 2008; 233(1): 76 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joyeux-Faure Cellular Protection by Erythropoietin: New Therapeutic Implications? J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fandrey A cordial affair - erythropoietin and cardioprotection Cardiovasc Res, October 1, 2006; 72(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 X Liu, Z Zhou, X Feng, Z Jia, Y Jin, and J Xu Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats. Postgrad. Med. J., September 1, 2006; 82(971): 588 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Feng Beyond erythropoiesis: The anti-inflammatory effects of erythropoietin Cardiovasc Res, September 1, 2006; 71(4): 615 - 617. [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure Cardiovasc Res, September 1, 2006; 71(4): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Mengozzi, R Latini, M Salio, A Sfacteria, G Piedimonte, J G Gerwien, M Leist, A L Siren, P Ghezzi, and S Chimenti Increased erythropoietin production after myocardial infarction in mice. Heart, June 1, 2006; 92(6): 838 - 839. [Full Text] [PDF]
|
|
|
|
|
|
C. Moon, M. Krawczyk, D. Paik, T. Coleman, M. Brines, M. Juhaszova, S. J. Sollott, E. G. Lakatta, and M. I. Talan Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, G. Takemura, Y. Li, S. Miyata, M. Esaki, H. Okada, H. Kanamori, N. C. Khai, R. Maruyama, A. Ogino, et al. Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy Circulation, January 31, 2006; 113(4): 535 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Noakes, P. E. di Prampero, C. Capelli, T. Zaobornyj, L. B Valdez, A. Boveris, M. Ashenden, T. W. Secomb, S. Dufour, E. Ponsot, et al. Comments on Point:Counterpoint "Positive effects of intermittent hypoxia (live high:train low) on exercise performance are/are not mediated primarily by augmented red cell volume" J Appl Physiol, December 1, 2005; 99(6): 2453 - 2462. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Vlagopoulos, H. Tighiouart, D. E. Weiner, J. Griffith, D. Pettitt, D. N. Salem, A. S. Levey, and M. J. Sarnak Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Kovacic Further Aspects of Anemia, Heart Failure, and Erythropoietin J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1549 - 1550. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fiordaliso, S. Chimenti, L. Staszewsky, A. Bai, E. Carlo, I. Cuccovillo, M. Doni, M. Mengozzi, R. Tonelli, P. Ghezzi, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury PNAS, February 8, 2005; 102(6): 2046 - 2051. [Abstract] [Full Text] [PDF]
|
|